Chromosomal microarray impacts clinical management

Clinical Genetics

Volumn 85, Issue 2, 2014, Pages 147-153

  Riggs, E R ^a   Wain, K E ^b   Riethmaier, D ^c   Smith Packard, B ^d   Faucett, W A ^d   Hoppman, N ^b   Thorland, E C ^b   Patel, V C ^a   Miller, D T ^e,f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c GENEDX   (United States)

^d GEISINGER HEALTH SYSTEM   (United States)

^e Division of Genetics   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Array comparative genomic hybridization; Chromosomal microarray analysis; Genetic testing; Patient care management

Indexed keywords

PAFAH1B1 PROTEIN; PROTEIN; RPS6KA3 PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AGYRIA; ARTICLE; CASE REPORT; CHILD; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL FEATURE; COFFIN LOWRY SYNDROME; CONTROLLED STUDY; COPY NUMBER VARIATION; DEVELOPMENTAL DISORDER; DISEASE MANAGEMENT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENETIC SERVICE; HAPLOINSUFFICIENCY; HUMAN; INSURANCE; INTRACTABLE EPILEPSY; MALE; MICROARRAY ANALYSIS; NEURONAL MIGRATION DISORDER; PAFAH1B1 GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; REIMBURSEMENT; RPS6KA3 GENE; SUBCORTICAL HETEROTOPIA; SYMPTOM ASSESSMENT; CLINICAL PRACTICE; DEVELOPMENTAL DISABILITIES; ECONOMICS; GENETICS; PHYSICIAN; PROCEDURES; STATISTICS AND NUMERICAL DATA;

DEVELOPMENTAL DISABILITIES; DISEASE MANAGEMENT; DNA COPY NUMBER VARIATIONS; GENETIC SERVICES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MICROARRAY ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS;

EID: 84892485770     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12107     Document Type: Article

References (38)

1. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 2010: 12 (11): 742-745.
2. Mefford HC, Batshaw ML, Hoffman EP. Genomics, intellectual disability, and autism. N Engl J Med 2012: 366 (8): 733-743.
3. Lu XY, Phung MT, Shaw CA et al. Genomic imbalances in neonates with birth defects: high detection rates by using chromosomal microarray analysis. Pediatrics 2008: 122 (6): 1310-1318.
4. Moeschler JB, Shevell M. Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics 2006: 117 (6): 2304-2316.
5. Shevell M, Ashwal S, Donley D et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology 2003: 60 (3): 367-380.
6. Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med 2008: 10 (4): 301-305.
7. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007: 120 (5): 1183-1215.
8. Miller DT, Adam MP, Aradhya S et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010: 86 (5): 749-764.
9. Sagoo GS, Butterworth AS, Sanderson S, Shaw-Smith C, Higgins JP, Burton H. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13, 926 subjects. Genet Med 2009: 11 (3): 139-146.
10. Hochstenbach R, van Binsbergen E, Engelen J et al. Array analysis and karyotyping: workflow consequences based on a retrospective study of 36, 325 patients with idiopathic developmental delay in the Netherlands. Eur J Med Genet 2009: 52 (4): 161-169.
11. Ravnan JB, Tepperberg JH, Papenhausen P et al. Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities. J Med Genet 2006: 43 (6): 478-489.
12. Ballif BC, Sulpizio SG, Lloyd RM et al. The clinical utility of enhanced subtelomeric coverage in array CGH. Am J Med Genet A 2007: 143A (16): 1850-1857.
13. Regier DA, Friedman JM, Marra CA. Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability. Am J Hum Genet 2010: 86 (5): 765-772.
14. Trevathan E. So what? Does the test lead to improved health outcomes? Neurology 2011: 77 (17): 1586-1587.
15. Coulter ME, Miller DT, Harris DJ et al. Chromosomal microarray testing influences medical management. Genet Med 2011: 13 (9): 770-776.
16. Mroch AR, Flanagan JD, Stein QP. Solving the puzzle: case examples of array comparative genomic hybridization as a tool to end the diagnostic odyssey. Curr Probl Pediatr Adolesc Health Care 2012: 42 (3): 74-78.
17. Adam MP, Justice AN, Schelley S, Kwan A, Hudgins L, Martin CL. Clinical utility of array comparative genomic hybridization: uncovering tumor susceptibility in individuals with developmental delay. J Pediatr 2009: 154 (1): 143-146.
18. Adams SA, Coppinger J, Saitta SC et al. Impact of genotype-first diagnosis: the detection of microdeletion and microduplication syndromes with cancer predisposition by aCGH. Genet Med 2009: 11 (5): 314-322.
19. Mississippi BCBSo. Chromosomal microarray (CMA) analysis for the Genetic Evaluation of Patients with Developmental Delay/Intellectual Disability or Autism Spectrum Disorder 2012, form http://www.bcbsms.com/index.php?q=provider-medical-policy-search.html&action=viewPolicy&path=%2Fpolicy%2Femed%2FChromosomal+Microarray+Analysis.html. Accessed on September 18, 2012.
20. Wellmark. Chromosomal Microarray (CMA) Analysis for the Genetic Evaluation of Patients with Developmental Delay/Intellectual Disability or Autism Spectrum Disorder 2012, from http://www.wellmark.com/Provider/MedPoliciesAndAuthorizations/MedicalPolicies/policies/Comparative_Genomic_Hybridization.aspx. Accessed on September 18, 2012.
21. Baldwin EL, Lee JY, Blake DM et al. Enhanced detection of clinically relevant genomic imbalances using a targeted plus whole genome oligonucleotide microarray. Genet Med 2008: 10 (6): 415-429.
22. Dobyns WB, Das S. (Updated March 3, 2009). LIS1-Associated Lissencephaly/Subcortical Band Heterotopia. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). , University of Washington, Seattle. 1997-2012, from http://www.genetests.org. Accessed on January 3, 2013.
23. Schneider K, Garber J. (Updated February 9, 2010). Li-Fraumeni Syndrome. 1993. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). , University of Washington, Seattle. 1997-2012, from http://www.genetests.org. Accessed on January 3, 2013.
24. Network NCC. Genetic/Familial High Risk Assessment: Breast and Ovarian 2012, from http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed on September 18, 2012.
25. Hunter AGW, Abidi FE. (Updated January 15, 2009). Coffin-Lowry Syndrome. 1993. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). , University of Washington, Seattle. 1997-2012, from http://www.genetests.org. Accessed on January 3, 2013.
26. Pereira PM, Schneider A, Pannetier S, Heron D, Hanauer A. Coffin-Lowry syndrome. Eur J Hum Genet 2010: 18 (6): 627-633.
27. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. J Clin Oncol 2002: 20 (6): 1480-1490.
28. Filipek PA, Accardo PJ, Ashwal S et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000: 55 (4): 468-479.
29. Shen Y, Dies KA, Holm IA et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010: 125 (4): e727-e735.
30. Roesser J. Diagnostic yield of genetic testing in children diagnosed with autism spectrum disorders at a regional referral center. Clin Pediatr 2011: 50 (9): 834-843.
31. Rauch A, Hoyer J, Guth S et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. Am J Med Genet A 2006: 140 (19): 2063-2074.
32. Battaglia A, Bianchini E, Carey JC. Diagnostic yield of the comprehensive assessment of developmental delay/mental retardation in an institute of child neuropsychiatry. Am J Med Genet 1999: 82 (1): 60-66.
33. Hagerman RJ, Wilson P, Staley LW et al. Evaluation of school children at high risk for fragile X syndrome utilizing buccal cell FMR-1 testing. Am J Med Genet 1994: 51 (4): 474-481.
34. de Vries BB, van den Ouweland AM, Mohkamsing S et al. Screening and diagnosis for the fragile X syndrome among the mentally retarded: an epidemiological and psychological survey. Collaborative Fragile X Study Group. Am J Hum Genet 1997: 61 (3): 660-667.
35. Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2011: 77 (17): 1629-1635.
36. Graham JM Jr, Kramer N, Bejjani BA et al. Genomic duplication of PTPN11 is an uncommon cause of Noonan syndrome. Am J Med Genet A 2009: 149A (10): 2122-2128.
37. Moreno-De-Luca D, Mulle JG, Kaminsky EB et al. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism and schizophrenia. Am J Hum Genet 2010: 87 (5): 618-630.
38. Timsit J, Bellanne-Chantelot C, Dubois-Laforgue D, Velho G. Diagnosis and management of maturity-onset diabetes of the young. Treat Endocrinol 2005: 4 (1): 9-18.